tiprankstipranks
Advertisement
Advertisement
Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley
PremiumThe FlyDenali Therapeutics price target lowered to $35 from $40 at Morgan Stanley
2M ago
Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank
Premium
The Fly
Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank
2M ago
Denali Therapeutics: Buy Rating Reiterated as TV Platform and Enzyme Portfolio Drive Long-Term Upside; $42 Price Target Maintained
Premium
Ratings
Denali Therapeutics: Buy Rating Reiterated as TV Platform and Enzyme Portfolio Drive Long-Term Upside; $42 Price Target Maintained
2M ago
Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
PremiumThe FlyBiogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
2M ago
Denali Therapeutics price target lowered to $40 from $42 at Morgan Stanley
Premium
The Fly
Denali Therapeutics price target lowered to $40 from $42 at Morgan Stanley
2M ago
Denali Therapeutics: AVLAYAH Momentum and Pipeline Progress Support Buy Rating, $39 Price Target Maintained
Premium
Ratings
Denali Therapeutics: AVLAYAH Momentum and Pipeline Progress Support Buy Rating, $39 Price Target Maintained
2M ago
Denali Therapeutics: Differentiated PGRN Strategy and AVLAYAH Strength Support Buy Rating and Higher $39 Target Despite Biology Risks
PremiumRatingsDenali Therapeutics: Differentiated PGRN Strategy and AVLAYAH Strength Support Buy Rating and Higher $39 Target Despite Biology Risks
3M ago
Denali Therapeutics price target raised to $39 from $38 at BTIG
Premium
The Fly
Denali Therapeutics price target raised to $39 from $38 at BTIG
3M ago
Denali Therapeutics regains full rights to DNL593
Premium
The Fly
Denali Therapeutics regains full rights to DNL593
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100